Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 2021

View Archived Issues

Recombinant hemagglutinin-expressing HSV vector offers protection against both HSV and influenza

Compound inhibits acute myeloid leukemia cells with FLT3-ITD mutations by targeting HSP70

Aston University descibres new antibacterials

New antivirals presented by EcoSynth, Transmare Chemie

Leiden University and collaborators patent monoglyceride lipase inhibitors

PTGER4 antagonists discovered at Hubei Bio-Pharmaceutical, Humanwell Healthcare

APMAP identified as a regulator of cancer cell phagocytosis

Kynurenine metabolites as biomarkers of chronic fatigue syndrome and fibromyalgia

Primate model of autism spectrum disorder reveals potential therapeutic targets

Identification of novel viral cleavage sites and potential therapeutic targets against SARS-CoV-2

Antibodies targeting glycosylated CD44 synthesized at Go Therapeutics

Different way of looking allows new insights into cancer biology

Elastase inhibition enhances the adjuvant activity of alum for SARS-CoV-2 vaccination

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...